The global market for ophthalmic drug delivery systems accounted for US$ 12,107 Mn in 2021 and is estimated to reach US$ 24,556 Mn by 2030, with a significant CAGR of 8.4% from 2022 to 2030.
Ophthalmic drug delivery systems are specialized dosage forms that are administered inside (intraocular), instilled onto the external surface of the eye (topical), administered adjacent to the eye (periocular), or used in association with an ophthalmic device. The need for ocular drug administration is primarily associated with the need to treat ophthalmic diseases. The eye is the most easily accessible site for topical medication administration. Ophthalmic drug delivery forms have been one of the most important and widely developed areas of pharmaceutical technology for a longer period. Ophthalmic drug delivery is one of the most desirable routes of drug administration because of the accurate dosing, ease of preparation and application, and high patient convenience and compliance. Gels, intravitreal injections, gel-forming solutions, implants, and ocular inserts are the most recent dosage forms for ophthalmic drug administration.
Market Growth Drivers
- Rising burden of eye disorders worldwide
- Rising number of ophthalmic procedures
- Technological advancements in ophthalmic drug delivery
Market Restraints
- Lack of trained ophthalmologists in emerging economies
- High cost of devices
Market Opportunities
- Growing demand from nanotechnology to get improved results
- Heavy investments in R&D activities
Report Coverage:
| Market |
Ophthalmic Drug Delivery Systems Market |
| Market Size 2021 |
US$ 12,107 Mn |
| Market Forecast 2028 |
US$ 24,556 Mn |
| CAGR |
8.4% During 2022 - 2030 |
| Analysis Period |
2018 - 2030 |
| Base Year |
2021 |
| Forecast Data |
2022 - 2030 |
| Segments Covered |
By Technology, By Production Technology, By Delivery Route, By Material, And By Geography
|
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Allergan plc, AptarGroup, Inc., Clearside Biomedical, Envisia Therapeutics, Ocular Therapeutix Inc., Oculis Pharma, pSivida, Santen Pharmaceutical Co. Ltd., and Valeant Pharmaceuticals. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation
|
Market Dynamics
The global ophthalmic drug delivery systems market is primarily driven by an increase in the number of eye disorders, as well as an increase in the population affected by them. Globally, at least 2.2 billion people have a near or distant vision impairment, according to the World Health Organization (WHO). The Blindness and Vision Impairment report (WHO) suggests that vision impairment may have been avoided or managed in at least 1 billion of these cases. The primary causes of vision impairment are age-related macular degeneration, cataracts, corneal opacity, diabetic retinopathy, glaucoma, uncorrected refractive errors, and trachoma among others. According to the National Center for Biotechnology Information (NCBI), the number of diabetic retinopathy (DR) patients will reach around 190 million by 2030. Thus, there are a slew of reasons for the prevalence of eye disorders throughout the world, resulting in escalated demand for the industry.
However, the market growth is confined due to the high cost of devices and the lack of trained ophthalmologists, especially in developing nations. Conversely, the market is also expected to witness numerous growth opportunities in the coming years. This could be attributed to the integration of nanotechnologies in drug delivery systems. Engineered nanostructures and nanodevices control human biological systems on a single-cell and molecular level. Nanoparticles (NPs) ranging in size from 10nanometer to 1000nanometer improved the topical course of huge, poorly water-soluble molecules through the ocular system's barriers. In this regard, nanomedicine has numerous advantages over drug-only treatments.
Market Segmentation
The global ophthalmic drug delivery systems market is segmented based on technology, production technology, delivery route, material, and geography.
Market By Technology
- Eye Drops
- Contact Lenses
- Punctal Plugs
- Episcleral Implants
- Others
Based on technologies, the eye drops segment is expected to achieve the leading market share in 2021. Eyedrops are the most common dosage form, accounting for 90% of all currently available ophthalmic formulations. Eye drops are the most commonly used method of administering medication to the eyes; they are simple to use and convenient for most patients. On the other hand, the micro-electromechanical sub-segment is likely to attain the fastest growth rate throughout the forecast period 2022 – 2030. Advantages such as targeted delivery to inner tissues, refillable to long-term use, and automated to address patient compliance are fueling the micro-electromechanical segment growth.
Market By Production Technology
- Electrospinning
- 3D Printing
- Extrusion
- Formulation
- Micro Patterning
- Compression Molding
- Others
In 2021, the formulation segment held a noteworthy amount of share in the production technology segment. The majority of drugs used in ocular therapy are administered via a topical formulation in the form of a solution or suspension. Because of rapid eye movements (blinking) and lacrimation, conventional formulations experience rapid clearance from the application site, resulting in low ocular availability. Meanwhile, the 3D printing segment is likely to attain a significant growth rate in the production technology.
Market By Delivery Route
- Intravitreal
- Intraocular
- Intracameral
The intraocular sub-segment captured the largest market share among delivery routes in 2021 and is expected to maintain its dominance throughout the forecast period. Intraocular administration of antibiotics is widely accepted as a standard treatment for endophthalmitis. However, the short duration of action of intraocular antimicrobials is their primary limitation. In addition, the intraocular delivery route offers which include ease of eye drop formulation, sterilization, and less irritation which also boosts the segmental growth.
Market By Material
- Liposomes
- Collagen
- PLA-PEG
- PDO/PVA
- Hydrogels
- TMC
- Others
By material, the hydrogels sub-segment is expected to gain a significant market share in the coming years. The market for hydrogels is expanding because they can be used in conjunction with other technologies to improve ocular drug delivery. It improves the bioavailability of topically applied formulations by extending the residence period of an active ingredient, allowing it to diffuse more thoroughly across the layers of the eye. In terms of growth, the polycaprolactone segment is likely to attain the fastest growth rate in the coming years 2022 – 2030.
Ophthalmic Drug Delivery Systems Market Regional Overview
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Middle East & Africa
- South Africa
- GCC
- Rest of Middle East & Africa
The growing burden of eye disorders in North America boosts the regional market growth
Based on the regional segmentation, the North American region occupied the leading market share all through the forecast period. The high growth in the region is credited to the presence of skilled ophthalmologists, the increasing incidence of ophthalmic disorders, and numerous government initiatives undertaken by government organizations to prevent blindness in the region. However, the Asia-Pacific region is expected to attain the fastest CAGR throughout the forecast timeframe. The presence of a large patient pool, a growing elderly population, and a rising preference for a sedentary lifestyle are some of the factors that are likely to create numerous growth opportunities for the Asia-Pacific ophthalmic drug delivery systems market.
Competitive Landscape
Some of the top vendors offered in the professional report include Allergan plc, AptarGroup, Inc., Clearside Biomedical, Envisia Therapeutics, Ocular Therapeutix Inc., Oculis Pharma, pSivida, Santen Pharmaceutical Co. Ltd., and Valeant Pharmaceuticals.
CHAPTER 1. Industry Overview of Ophthalmic Drug Delivery Systems Market
1.1. Definition and Scope
1.1.1. Definition of Ophthalmic Drug Delivery Systems
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Ophthalmic Drug Delivery Systems Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Ophthalmic Drug Delivery Systems Market By Technology
1.2.3. Ophthalmic Drug Delivery Systems Market By Production Technology
1.2.4. Ophthalmic Drug Delivery Systems Market By Delivery Route
1.2.5. Ophthalmic Drug Delivery Systems Market By Material
1.2.6. Ophthalmic Drug Delivery Systems Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Ophthalmic Drug Delivery Systems Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Ophthalmic Drug Delivery Systems Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material Cost
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2021
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021
4.2. R&D Status of Major Manufacturers in 2021
CHAPTER 5. Ophthalmic Drug Delivery Systems Market By Technology
5.1. Introduction
5.2. Ophthalmic Drug Delivery Systems Revenue By Technology
5.2.1. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast, By Technology, 2018-2030
5.2.2. Eye Drops
5.2.2.1. Eye Drops Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
5.2.3. Contact Lenses
5.2.3.1. Contact Lenses Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
5.2.4. Punctal Plugs
5.2.4.1. Punctal Plugs Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
5.2.5. Episceral Implants
5.2.5.1. Episceral Drops Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
5.2.6. Others
5.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 6. Ophthalmic Drug Delivery Systems Market By Production Technology
6.1. Introduction
6.2. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) By Production Technology
6.2.1. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
6.2.2. Electrospinning
6.2.2.1. Electrospinning Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.3. 3D Printing
6.2.3.1. 3D Printing Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.4. Extrusion
6.2.4.1. Extrusion Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.5. Formulation
6.2.5.1. Formulation Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.6. Micro Patterning
6.2.6.1. Micro Patterning Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.7. Compression Molding
6.2.7.1. Compression Molding Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
6.2.8. Others
6.2.8.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 7. Ophthalmic Drug Delivery Systems Market By Delivery Route
7.1. Introduction
7.2. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) By Delivery Route
7.2.1. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
7.2.2. Intravitreal
7.2.2.1. Intravitreal Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
7.2.3. Intracaramel
7.2.3.1. Intraocaramel Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
7.2.4. Intraocular
7.2.4.1. Intraocular Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 8. Ophthalmic Drug Delivery Systems Market By Material
8.1. Introduction
8.2. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) By Material
8.2.1. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
8.2.2. Liposomes
8.2.2.1. Liposomes Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.3. Collagen
8.2.3.1. Collagen Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.4. PDO/PVA
8.2.4.1. PDO/PVA Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.5. Hydrogels
8.2.5.1. Liposomes Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.6. PLA-PEG
8.2.6.1. PLA-PEG Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.7. TMC
8.2.7.1. TMC Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
8.2.8. Others
8.2.8.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2018-2030
CHAPTER 9. North America Ophthalmic Drug Delivery Systems Market By Country
9.1. North America Ophthalmic Drug Delivery Systems Overview
9.2. U.S.
9.2.1. U.S. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
9.2.2. U.S. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
9.2.3. U.S. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
9.2.4. U.S. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
9.3. Canada
9.3.1. Canada Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
9.3.2. Canada Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
9.3.3. Canada Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
9.3.4. Canada Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
9.4. North America PEST Analysis
CHAPTER 10. Europe Ophthalmic Drug Delivery Systems Market By Country
10.1. Europe Ophthalmic Drug Delivery Systems Overview
10.2. U.K.
10.2.1. U.K. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
10.2.2. U.K. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
10.2.3. U.K. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
10.2.4. U.K. Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
10.3. Germany
10.3.1. Germany Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
10.3.2. Germany Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
10.3.3. Germany Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
10.3.4. Germany Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
10.4. France
10.4.1. France Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
10.4.2. France Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
10.4.3. France Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
10.4.4. France Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
10.5. Spain
10.5.1. Spain Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
10.5.2. Spain Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
10.5.3. Spain Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
10.5.4. Spain Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
10.6. Rest of Europe
10.6.1. Rest of Europe Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
10.6.2. Rest of Europe Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
10.6.3. Rest of Europe Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
10.6.4. Rest of Europe Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Ophthalmic Drug Delivery Systems Market By Country
11.1. Asia Pacific Ophthalmic Drug Delivery Systems Overview
11.2. China
11.2.1. China Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.2.2. China Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.2.3. China Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.2.4. China Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.3. Japan
11.3.1. Japan Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.3.2. Japan Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.3.3. Japan Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.3.4. Japan Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.4. India
11.4.1. India Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.4.2. India Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.4.3. India Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.4.4. India Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.5. Australia
11.5.1. Australia Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.5.2. Australia Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.5.3. Australia Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.5.4. Australia Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.6. South Korea
11.6.1. South Korea Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.6.2. South Korea Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.6.3. South Korea Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.6.4. South Korea Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
11.7.2. Rest of Asia-Pacific Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
11.7.3. Rest of Asia-Pacific Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
11.7.4. Rest of Asia-Pacific Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Ophthalmic Drug Delivery Systems Market By Country
12.1. Latin America Ophthalmic Drug Delivery Systems Overview
12.2. Brazil
12.2.1. Brazil Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
12.2.2. Brazil Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
12.2.3. Brazil Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
12.2.4. Brazil Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
12.3. Mexico
12.3.1. Mexico Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
12.3.2. Mexico Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
12.3.3. Mexico Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
12.3.4. Mexico Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
12.4. Rest of Latin America
12.4.1. Rest of Latin America Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
12.4.2. Rest of Latin America Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
12.4.3. Rest of Latin America Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
12.4.4. Rest of Latin America Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Ophthalmic Drug Delivery Systems Market By Country
13.1. Middle East & Africa Ophthalmic Drug Delivery Systems Overview
13.2. GCC
13.2.1. GCC Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
13.2.2. GCC Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
13.2.3. GCC Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
13.2.4. GCC Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
13.3. South Africa
13.3.1. South Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
13.3.2. South Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
13.3.3. South Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
13.3.4. South Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Technology, 2018-2030
13.4.2. Rest of Middle East & Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Production Technology, 2018-2030
13.4.3. Rest of Middle East & Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Delivery Route, 2018-2030
13.4.4. Rest of Middle East & Africa Ophthalmic Drug Delivery Systems Revenue (US$ Mn) and Forecast By Material, 2018-2030
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Ophthalmic Drug Delivery Systems Market
14.1. Ophthalmic Drug Delivery Systems Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Technology Launches and Technology Enhancements
14.2.3. Mergers And Acquisition In Global Ophthalmic Drug Delivery Systems market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. Allergan plc
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (US$ Mn), 2021
15.1.3.2. Allergan plc2021 Ophthalmic Drug Delivery Systems Business Regional Distribution
15.1.4. Product/Service and Specification
15.1.5. Recent Developments & Business Strategy
15.1.6. Manufacturing Plant Footprint Analysis
15.2. AptarGroup, Inc.
15.3. Clearside Biomedical
15.4. Envisia Therapeutics
15.5. Ocular Therapeutix Inc.
15.6. Oculis Pharma
15.7. pSivida
15.8. Santen Pharmaceutical Co. Ltd.
15.9. Valeant Pharmaceuticals
